Jacob Bell
New Member
Author(s) Snider S.R, Consroe P.
Journal, Volume, Issue Neurology 1984;34(Suppl):147.
Major outcome(s) 50% improvement in spasm severity and frequency
Indication Dystonia
Medication Cannabidiol
Route(s) Oral
Dose(s)
Duration (days)
Participants A 42 year old Meige syndrome patient
Design Uncontrolled case report
Type of publication Medical journal
Abstract
Cannabidiol (CBD) is the major nonpsychoactive cannabinoid in marijuana. The anticonvulsant properties of CBD were demonstrated in humans 5 years ago. Based on anecdotal reports of improvement of generalized dystonia with marijuana smoking, we decided to try CBD in a patient with severe cranial dystonia (Meige syndrome). The patient, a 42-year-old man, first developed mild blepharospasm 9 years ago. The abnormal movements gradually spread to the oromandibular and neck muscles and worsened to the point that the patient was unable to drive. Many drugs were tried, with disappointing results. CBD was initiated at 100 mg/day, in divided doses, and slowly increased over several weeks to 400 mg/day. Other drugs were kept the same. Spasm frequency, counted twice daily by a relative while the patient was either talking or driving, gradually decreased from 20 to 30 per min before CBD to 7 or 15 per min at a dosage of 400 mg/day. Examinations at weekly intervals using a standard rating scale confirmed at least 50 % improvement in spasm severity and frequency. Withdrawal of CBD for 24 hours resulted in reappearance of severe spasm at 25 to 30 per min. Side effects included dry mouth, transient morning headache, and slight sedation.
Source: Treatment of Meige's Syndrome with Cannabidiol
Journal, Volume, Issue Neurology 1984;34(Suppl):147.
Major outcome(s) 50% improvement in spasm severity and frequency
Indication Dystonia
Medication Cannabidiol
Route(s) Oral
Dose(s)
Duration (days)
Participants A 42 year old Meige syndrome patient
Design Uncontrolled case report
Type of publication Medical journal
Abstract
Cannabidiol (CBD) is the major nonpsychoactive cannabinoid in marijuana. The anticonvulsant properties of CBD were demonstrated in humans 5 years ago. Based on anecdotal reports of improvement of generalized dystonia with marijuana smoking, we decided to try CBD in a patient with severe cranial dystonia (Meige syndrome). The patient, a 42-year-old man, first developed mild blepharospasm 9 years ago. The abnormal movements gradually spread to the oromandibular and neck muscles and worsened to the point that the patient was unable to drive. Many drugs were tried, with disappointing results. CBD was initiated at 100 mg/day, in divided doses, and slowly increased over several weeks to 400 mg/day. Other drugs were kept the same. Spasm frequency, counted twice daily by a relative while the patient was either talking or driving, gradually decreased from 20 to 30 per min before CBD to 7 or 15 per min at a dosage of 400 mg/day. Examinations at weekly intervals using a standard rating scale confirmed at least 50 % improvement in spasm severity and frequency. Withdrawal of CBD for 24 hours resulted in reappearance of severe spasm at 25 to 30 per min. Side effects included dry mouth, transient morning headache, and slight sedation.
Source: Treatment of Meige's Syndrome with Cannabidiol
